Induction Chemotherapy in Advanced Head and Neck Cancer Preliminary results of a randomized study

Authors

  • F. Brunin Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • J. Rodriguez Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • C. Jaulerry Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • M. Jouve Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • D. Pontvert Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • D. Point Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • V. Mosseri Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • P. Pouillart Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • B. Asselain Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • J. Brugere Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France
  • J. P. Bataini Department of Radiotherapy, Head and Neck Surgery, Clinical Oncology, and Clinical Research, Curie Institute, Paris, France

DOI:

https://doi.org/10.3109/02841868909111183

Keywords:

Head and neck cancer, advanced tumors, radio therapy, induction chemotherapy, cisplatin, bleomycin, vinde sine, mitomycin C, primary response, survival, randomized trial

Abstract

From March 1983 to June 1986, 100 patients with locally advanced squamous cell carcinoma of the head and neck were randomized to receive either two courses of chemotherapy prior to local therapy (group A), or local therapy alone (group B). Local treatment consisted of primary radiotherapy in all patients. When a poor response was observed after 55 Gy, surgery was performed. The chemotherapy regimen was a combination of cisplatinum, bleomycin, vindesine, and mitomycin C. The response rate to induction chemotherapy (group A) was 50% for the primary tumor (CR: 10% and PR: 40%). At the end of radiotherapy, the overall tumor response rates in the two groups A and B, were 77% and 79% respectively. Complete disappearance of the primary tumor occurred more often than that of the lymph node metastases. The response rate to induction chemotherapy for lymph node metastases was 27.1 % (CR: 9% and PR: 18.1 %). An initial major response to chemotherapy predicted subsequent efficacy of irradiation on 90% of the cases, while a failure of chemotherapy had no predictive value in this respect. The survival rates in groups A and B were 66.5% vs. 65.1% at 1 year and 35% vs. 46.2% at 2 years. Local disease-free and disease-free intervals were similar in both groups. A Cox's multi-step regression analysis revealed two significant independant prognostic factors: size of primary tumor and nodal status. 

Downloads

Download data is not yet available.

Downloads

Published

1989-01-01

How to Cite

Brunin, F. ., Rodriguez, J. ., Jaulerry, C., Jouve, M. ., Pontvert, D. ., Point, D., … Bataini, J. P. . (1989). Induction Chemotherapy in Advanced Head and Neck Cancer Preliminary results of a randomized study. Acta Oncologica, 28(1), 61–65. https://doi.org/10.3109/02841868909111183